Search Results - Homan-Weert, Paola

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma

    NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma by Verkleij, Christie P.M., Frerichs, Kristine A., Broekmans, Marloes E.C., Duetz, Carolien, O'Neill, Chloe A., Bruins, Wassilis S.C., Homan‐Weert, Paola M., Minnema, Monique C., Levin, Mark‐David, Broijl, Annemiek, Bos, Gerard M.J., Kersten, Marie José, Klein, Saskia K., Shikhagaie, Medya M., Casneuf, Tineke, Abraham, Yann, Smets, Tina, Vanhoof, Greet, Cortes‐Selva, Diana, Steenbergen, Laure, Ramos, Elena, Verona, Raluca I., Krevvata, Maria, Sonneveld, Pieter, Zweegman, Sonja, Mutis, Tuna, Donk, Niels W.C.J.

    Published in HemaSphere
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Baseline CD57 + and CD16 + NK-Cells Predict Treatment Outcome in Non-Transplant Eligible Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Ixazomib-Dexamethasone

    Baseline CD57 + and CD16 + NK-Cells Predict Treatment Outcome in Non-Transplant Eligible Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Ixazomib-Dexamethasone by Bruins, Wassilis S.C, Duetz, Carolien, Groen, Kaz, Korst, Charlotte L.B.M., de Jonge, A.Vera, Rentenaar, Rosa, Cosovic, Meliha, Eken, Merve, Twickler, Inoka, Homan-Weert, Paola, Verkleij, Christie P.M., Frerichs, Kristine A., van de Donk, Niels WCJ, Zweegman, Sonja, Mutis, Tuna

    Published in Blood
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    CD16, CD57 and DNAM-1 Positive NK Cells Predict MRD Negativity in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Bortezomib, Thalidomide and Dexamethasone

    CD16, CD57 and DNAM-1 Positive NK Cells Predict MRD Negativity in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Bortezomib, Thalidomide and Dexamethasone by Korst, Charlotte L.B.M., Duetz, Carolien, Bruins, Wassilis S.C, de Jonge, A. Vera, Groen, Kaz, Verkleij, Christie P.M., Frerichs, Kristine A., Cosovic, Meliha, Twickler, Inoka, Rentenaar, Rosa, Eken, Merve, Homan-Weert, Paola, Moreau, Philippe, Sonneveld, Pieter, Zweegman, Sonja, Mutis, Tuna, Van De Donk, Niels W.C.J.

    Published in Blood
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Immune Profiling of Multiple Myeloma Patients Treated with Daratumumab Monotherapy: Acquired and Primary Daratumumab-Resistance Is Associated with NK Cell Exhaustion

    Immune Profiling of Multiple Myeloma Patients Treated with Daratumumab Monotherapy: Acquired and Primary Daratumumab-Resistance Is Associated with NK Cell Exhaustion by Verkleij, Christie P.M., Frerichs, Kristine A., Duetz, Carolien, Zweegman, Sonja, Homan-Weert, Paola M., Minnema, Monique C., Broyl, Annemiek, Levin, Mark-David, Bos, Gerard M.J., Kersten, Marie José, Klein, Saskia K., Shikhagaie, Medya M., Krevvata, Maria, Casneuf, Tineke, Abraham, Yann, Verona, Raluca I., Smets, Tina, Vanhoof, Greet, Cortes-Selva, Diana, van Steenbergen, Laure, Vieyra, Diego, Sonneveld, Pieter, Mutis, Tuna, van de Donk, Niels W.C.J.

    Published in Blood
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: